Is tnxp a good buy now

**Tonix Pharmaceuticals Holding Corp. (TNXP) does not appear to be a good buy at this time.** Here's why:

1. **Recent Price Volatility**: The stock experienced a significant drop of 83.46% from June 6 to July 5, 2024, which is a concerning sign of market volatility. This recent price decline could be indicative of underlying issues with the company or the broader market conditions affecting the stock.

|Ticker|Name|Interval Percentage Change|Closing Price|Date|code|market_code|
|---|---|---|---|---|---|---|
|TNXP.O|Tonix|-83.46354166666666||20240606-20240705|TNXP|186|
|TNXP.O|Tonix|15.95652173913045||20240628-20240705|TNXP|186|
|TNXP.O|Tonix||0.8001|20240705|TNXP|186|

2. **Technical Indicators Suggest Caution**: The stock's 5-day moving average is $0.77, its 10-day moving average is $0.94, and its 20-day moving average is $1.38. The short-term moving averages are below the long-term averages, which could suggest a bearish trend. Additionally, the stock's resistance level is at $0.95 and its support level is at $0.79, indicating a narrow trading range with limited upside potential.

|Ticker|Name|5-Day Moving Average|20-Day Moving Average|10-Day Moving Average|Date|code|market_code|
|---|---|---|---|---|---|---|---|
|TNXP.O|Tonix|0.7721|1.3804|0.9416|20240705|TNXP|186|

|Ticker|Name|Support Level|Resistance Level|Date|code|market_code|
|---|---|---|---|---|---|---|
|TNXP.O|Tonix|0.7901|0.9500|20240705|TNXP|186|

3. **Market Sentiment and Analysts' Views**: There is no recent news or analyst reports that would indicate a positive outlook for TNXP. The absence of positive news or analyst recommendations could be a deterrent for investors looking for a stock with positive momentum or growth prospects.
4. **Business and Development Challenges**: Tonix Pharmaceuticals is developing a pipeline of therapeutics for various indications, including fibromyalgia, rare diseases, immunology, and infectious diseases. While this is a positive aspect for long-term growth, the company's focus on development and regulatory approvals could lead to delays in revenue generation.
5. **Financial Projections**: The company's revenue estimate for 2024 is $13.92 million, with a high estimate of $15.8 million. These figures suggest that the company's revenue growth may be limited in the near term, which could impact the stock's valuation.

In conclusion, given the recent price decline, lack of positive news or analyst recommendations, and the company's focus on long-term development, TNXP does not appear to be a good buy at this time. Investors should exercise caution and consider these factors before making an investment decision.